HLB Pharmaceutical Starts $41.4 Million Tablet Plant in Hwaseong, South Korea
HLB Pharmaceutical begins building a 55 billion won tablet plant in Hwaseong, boosting capacity to 700 million tablets by 2029 to reach 1 trillion won sale
Research Desk
HLB Pharmaceutical has begun construction of a new tablet manufacturing plant in the Hyangnam area of Hwaseong, Gyeonggi Province, backed by an investment of USD 41.4 million.
Targeting USD 749.19 million by 2036
The groundbreaking took place on Thursday and forms part of the drugmaker's plan to reach USD 749.19 million in annual sales by 2036 and rank among Korea's 10 largest pharmaceutical companies. Chairman Jin Yang-gon of HLB Group attended the ceremony and said the plant would concretely realize the group's corporate mission of "Human Life Better," describing it as "a production site that can be trusted by any standards with top-level quality and cutting-edge equipment."
Nearly triple current output
The Hyangnam facility is expected to produce about 700 million tablets annually, close to three times the roughly 250 million tablets a year currently made at the company's Namyangju plant. CEO Park Jae-hyung said the existing capacity had made it difficult to keep up with rising demand, forcing the company to lean heavily on external production.
"The new Hyangnam plant, which breaks ground today, is our answer to this task," Park said at the ceremony. The plant will consist of manufacturing facilities and auxiliary buildings with one basement level and three floors above ground, spanning 11,931 square meters on a 31,244-square-meter site.
Timeline to full operation
Construction is due to finish by late 2027, with building-use approval targeted for the end of that year. After regulatory procedures, including Good Manufacturing Practice certification, the company plans to gradually shift manufacturing from Namyangju and begin full-scale production at Hyangnam in 2029. HLB Pharmaceutical said the investment is intended to bring more production in-house, cut reliance on outside contract manufacturers and improve cost advantages.
The added capacity is also expected to back new product launches and the growth of its contract manufacturing organization, or CMO, business. The company described the site as a key manufacturing hub for HLB Group's pharmaceutical operations, supporting production of new drugs across the group, and said it is weighing further expansion of manufacturing infrastructure on adjacent land.
Record sales underpin the buildout
The move follows strong results. HLB Pharmaceutical posted USD 154.03 million in sales last year, crossing the USD 149.84 million threshold for the first time, and continued that momentum with a record USD 95.82 million in sales in the first half of this year, covering January to June.
Phased decade-long plan
The company's 10-year roadmap to 2036 unfolds in stages. From 2027 to 2028, the focus is on improving profitability. Between 2029 and 2031, HLB Pharmaceutical aims to strengthen its prescription drug portfolio through improved-drug development and expanded sales at general hospitals. After that, it plans to broaden its presence in oncology, urology and rare diseases while pursuing the introduction of blockbuster products and strategic mergers and acquisitions.
The overall strategy also includes strengthening the prescription drug business, developing improved versions of existing drugs and introducing new products. "Going beyond developing new cancer drugs, we will take a leap into becoming a company that stably supplies good drugs wanted by patients and medical staff to the world," Jin said.
Tracked in the database
Facility expansion · Asia-Pacific
Facility expansion
Asia-Pacific
Industrial
12 November 2026
3 min read
Tagged
Also read
Biocon Secures European Commission Approval for Pertuzumab Biosimilar Pebrilzo in HER2-Positive Breast Cancer
Nanoform Partners With European CDMO to Manufacture High-Concentration Biologics Under GMP in Germany
LOTTE Biologics Signs First Commercial Manufacturing Agreement for Songdo Plant 1 in South Korea
Live from the tracker
The projects behind these stories
Capacity, capex, stage, contractors and verified contacts for every project we track, updated daily.